365mc held a grand opening ceremony for its liposuction-focused medical institution in Los Angeles Calif., signaling a new chapter in its global expansion strategy. The event took place on Sept. 24 (local time) at the Orange County site of 365mc LA.

365mc CEO Kim Nam-chul (right of the company’s mascot in center) pose for a photo with guests and employees in front of the company’s new clinic in Los Angeles, Calif. on Sept. 24. (Credit: 365mc)
365mc CEO Kim Nam-chul (right of the company’s mascot in center) pose for a photo with guests and employees in front of the company’s new clinic in Los Angeles, Calif. on Sept. 24. (Credit: 365mc)

The LA branch’s flagship procedure is the company’s proprietary Localized Anesthesia-based Minimally Invasive Liposuction System (LAMS). The clinic is led by Dr. Angie Trias Sanchez as chief physician, joined by co-director and nurse practitioner Maria Samanda Layson, both of whom completed training in Korea earlier this year under the company’s veteran medical team.

“LAMS is a groundbreaking technology developed by 365mc, combining safety, precision, and minimal incisions,” Sanchez said. “With the added LEPA system to predict outcomes, it represents an innovation rarely seen even in the U.S., a leading country in aesthetic medicine.”

K-LAMS offers differentiated competitiveness in the U.S. liposuction market and will contribute to elevating the global reputation of Korean medical technology, she added.

Expanding beyond Asia into the U.S.

The U.S. entry follows 365mc’s expansion across Asia, including Indonesia and Thailand, bringing its overseas network to five branches. A clinic in Ho Chi Minh City, Vietnam, is scheduled to open soon.

The company has also strengthened its global partnerships. In July, it signed a strategic collaboration with Israel-based Raziel Therapeutics to develop next-generation non-surgical fat reduction solutions.

The partnership aims to combine 365mc’s LAMS procedure with Raziel’s investigational fat-dissolving injection RZL-012, which is poised to enter phase 3 clinical trials with the U.S. FDA. Pending approval, the treatment is expected to be introduced at the LA clinic.

“After securing the LA clinic, we will move forward with expansion to major U.S. cities such as New York, Chicago, and Seattle,” 365mc CEO Kim Nam-chul said. “365mc will continue to tailor its strategies to local standards of beauty and build trust through AI-based personalized treatments.”

The hospital’s goal is to become a core global medical institution leading obesity treatment trends, so that when people think of liposuction anywhere in the world, they think of 365mc, Kim added.

Related articles

Copyright © KBR Unauthorized reproduction, redistribution prohibited